Teva flags supply constraints to ADHD drug Adderall as demand rises (NYSE: TEVA) | Seeking Alpha
Future Teva CEO Seeks to 'Formulate Clear Strategy' - YouTube
Teva Pharmaceuticals Names Kare Schultz As New CEO | Fortune
Teva (TEVA) Agrees to $225 Million Texas Opioid Settlement, AG Says - Bloomberg
Teva Pharma's Short Sellers Double Down as Legal Woes Drag On - BNN Bloomberg
Price-fixing lawsuit deals another blow to already fragile Teva, experts say | The Times of Israel
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
Activist Investor Jana Partners Takes Stake in Teva, Report Says | Ctech
Teva Analysts Say Migraine Drug Approval Gives Needed Relief - Bloomberg
Teva's $15B free drug opioid settlement might be a great deal in the long run: analyst | Fierce Pharma
Teva shares jump in Tel Aviv after report of up to 10,000 job cuts | The Times of Israel
Teva says its generic Adderall shortage will last another 2 to 3 months (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York State | CNN
Tags search | Ctech
Teva Pharmaceutical to Replace CEO Kare Schultz - WSJ
The Difficulties of Cloning a CEO - Bloomberg
Teva CEO to Meet Netanyahu With Blunt Message on Need for Cuts - Bloomberg
Teva Wins UK Challenge Over Key Novartis Drug Patents (1)
Teva Pharma's Short Sellers Double Down as Legal Woes Drag On - Bloomberg
Teva considering cutting up to 10,000 jobs: Bloomberg | Reuters
Teva's Budding Blockbuster Drugs Lend Respite From Legal Concerns - Bloomberg
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
